Abstract:In myeloid malignancies including acute myeloid leukaemia and myelodysplastic syndrome, mutations in spliceosome components drive aberrant RNA splicing and tumourigenesis. Numerous therapeutic strategies have been employed to target this aberrant splicing and achieve splicing‐mutant cell death. Attempted approaches include drugs binding specific spliceosome components, promotion of splicing factor degradation, oligonucleotide therapeutics, and inhibition of splicing factor signalling, methylation, and phosphorylation. Summary In recent years, large‐scale sequencing efforts have identified targetable driver mutations in haematopoietic stem cells. These efforts have led to the development and approval of nine novel agents for relapsed or refractory acute myelogenous leukaemia (R/R AML). However, despite an expansion in targeted therapies, achieving a durable remission in AML and high‐risk myelodysplastic syndrome (HR‐MDS) remains a significant challenge, and there is an urgent need for new effective treatments. Modulation of aberrant RNA splicing has emerged as a novel therapeutic approach in myeloid diseases. Aberrant splicing drives dysregulated gene expression that promotes tumourigenesis through increased proliferation and metastatic potential, immune evasion, decreased apoptosis, and chemotherapy resistance. Mutations in spliceosomal components have been identified in numerous cancer subtypes, with mutations in RNA binding proteins SF3B1, SRSF2, U2AF1, and ZRSR2 occurring frequently in AML and in up to 60% of patients with MDS, as well as in chronic myelomonocytic leukaemia and in 10% of patients with chronic lymphocytic leukaemia. In this review, we explore therapeutic strategies targeting aberrant splicing and the potential of these approaches to drive clinical responses.

The Role of RNA Splicing in Liver Function and Disease: A Focus on Metabolic Dysfunction-Associated Steatotic Liver Disease

RNA Splicing: A Versatile Regulatory Mechanism in Pediatric Liver Diseases

Alternative RNA Splicing in Fatty Liver Disease

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death

Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

Dysregulation and therapeutic targeting of RNA splicing in cancer

RNA mis-splicing in disease

Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects

Splicing Factor SRSF1 Deficiency in the Liver Triggers NASH-like Pathology via R-Loop Induced DNA Damage and Cell Death

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

RNA Splicing Alterations in Lung Cancer Pathogenesis and Therapy

Targeting RNA-Splicing for SMA Treatment

Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets

RNA structure in alternative splicing regulation: from mechanism to therapy

Towards Understandings of Serine/arginine-Rich Splicing Factors

Therapeutic potential of alternative splicing in cardiovascular diseases

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Spatial genomics: mapping human steatotic liver disease